1	Differential Results of Polygenic Risk Scoring for Multiple Sclerosis		
2		in Europea	n and African American Populations
3			
4	Cyprien A. Rivier MD	MSc <sup>1-2</sup> , Seyed	nehdi Payabvash MD, Hongyu Zhao PhD, David A. Hafler MD <sup>1</sup> ,
5	Guid	lo J. Falcone N	D, ScD, MPH <sup>1,2</sup> *, Erin E. Longbrake MD/PhD <sup>1</sup> *
6			
7	1. Department of	Neurology, Ya	e School of Medicine, New Haven, CT, USA.
8	2. Yale Center fo	r Brain and Mir	d Health, Yale School of Medicine, New Haven, CT, USA.
9			
10	*Jointly supervised this	s work.	
11			
12			
13			
14	Corresponding author	or:	
15	Guido J. Falcone, MD,	ScD, MPH	Erin Longbrake MD/PhD
16	100 York Street, Suite	1-N	6 Devine Street, Ste Suite 2B
17	PO Box 208018		
18	New Haven, CT 06511	, USA	North Haven, CT 06473
19	Phone: +1 (203) 785-6	288	
20	Fax: +1 (203) 737-441	9	
21			
22	Title character count:	15	No. of references: 15
23	Word count abstract:	292	No. of tables: 1
24	Word count article:	1947	No. of figures: 2
25			

26	Abstract
27	
28	Importance: The risk of multiple sclerosis (MS) is significantly influenced by polygenic
29	inheritance. Polygenic risk scores (PRS) for MS can help identify high-risk individuals and stratify
30	populations for clinical trials. However, most genome-wide association studies (GWAS) have
31	been conducted in populations of European ancestry, raising questions about the accuracy of
32	these PRS in other ancestries.
33	
34	Objective: To determine whether a PRS for MS can effectively stratify individuals of non-
35	European ancestries.
36	European ancesmes.
37	Design acting and participanta. This grass sectional study utilized prospectively collected data
	<b>Design, setting and participants:</b> This cross-sectional study utilized prospectively collected data
38	from the All of Us Research Program (2018-2023). It included participants who had both whole
39	genome sequencing and electronic health record (EHR) data.
40	
41	Exposure(s): A PRS comprising 282 independent single nucleotide variants for MS, divided into
42	quintiles.
43	
44	Main Outcome(s) and Measure(s): Prevalence of multiple sclerosis ascertained through ICD-10
45	or SNOMED codes.
46	
47	Results: In this study population, MS cases comprised 1.0% (327 cases) of the European
48	population, 0.56% (183 cases) of the African population, and 0.46% (150 cases) of the
49	Latino/admixed American population. In analyses adjusting for age, sex, and genetic principal
50	components, the PRS associates with MS risk in the European population, with a 141% increase
51	in the risk of MS for individuals in the highest compared to the lowest PRS quintile (OR: 2.41
52	[1.69-3.50], test-for-trend p<0.001). Similarly, the PRS appropriately partitions the Latino/admixed
53	population into increasing MS risk groups (OR: 2.56 [1.45-4.78], test-for-trend p-value <0.001).
54	However, it did not significantly stratify the African population into distinct MS risk categories (OR:
55	1.45 [0.95-2.25], test-for-trend p=0.10).

57	Conclusions and Relevance: A PRS for MS effectively stratified individuals of European and
58	Latino/admixed ancestries but not African ancestry. This highlights the need for ancestry-specific
59	PRS development to ensure accurate risk prediction across diverse populations, emphasizing the
60	importance of including non-European groups in MS genetic research.
61	
62	

63	Introduction
64	Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by inflammation and
65	demyelination in the central nervous system, leading to a range of neurological symptoms and
66	disabilities <sup>1</sup> . The etiology of MS is complex, involving both genetic and environmental factors <sup>1</sup> .
67	Advances in genomic technologies have significantly contributed to our understanding of the genetic
68	architecture of MS, revealing that polygenic inheritance plays a crucial role in the disease's
69	development <sup>2</sup> . At present, 333 single nucleotide polymorphisms (SNPs) have been associated with
70	risk of MS <sup>3</sup> , most are common variants that are associated with only modest increases in risk.
71	However, the cumulative genetic burden of these loci may represent an important biomarker that is
72	able to differentiate between those with high and low risk of future disease <sup>4</sup> .
73	
74	Polygenic risk scores (PRS) have emerged as a powerful tool to quantify an individual's cumulative
75	genetic predisposition to complex diseases like MS <sup>5</sup> . PRS aggregate the effects of numerous genetic
76	variants into a single score that can be used to predict disease risk. This method has shown promise
77	in identifying high-risk individuals. Importantly, clinical trials evaluating lipid-lowering therapies have
78	shown significant heterogeneity of treatment effects across categories of polygenic risk, with study
79	participants at highest polygenic risk deriving larger benefits <sup>6</sup> . However, most genome-wide
80	association studies (GWAS) that inform PRS development have predominantly involved populations
81	of European ancestry <sup>7</sup> . This raises concerns about the applicability and accuracy of PRS in
82	individuals of non-European ancestries, potentially leading to disparities in disease prediction and
83	prevention efforts.
84	
85	To address this gap, our study aims to evaluate the effectiveness of an MS-related PRS based on the
86	known genetic architecture of the disease within different ancestry groups. The All of Us Research
87	Program <sup>8</sup> aims to enroll an ethnically diverse group of 1 million Americans to accelerate biomedical
88	research and reduce health disparities. All of Us is generating whole genome sequencing data and
89	incorporates complete electronic health records (EHR) data. Using All of Us, we sought to determine
90	whether a PRS developed primarily from European ancestry data could effectively stratify individuals

- 91 of African and Latino/admixed American (L/A) ancestries into distinct MS risk categories. Given the
- 92 underrepresentation of non-European populations in genetic research, this study provides an

93 essential assessment of PRS utility in diverse groups, thereby contributing to more equitable and

94 accurate genetic risk assessment in MS.

95

96

## Methods

# 97 Study design and inclusion criteria

98 We conducted a cross-sectional genetic study within the All of Us Research Program<sup>8</sup>, an ongoing 99 study in the US that aims to enroll 1 million Americans aged 18 and older. All of Us does not focus on 100 any particular disease or health status and emphasizes recruitment of groups that have been 101 historically underrepresented in biomedical research. All of Us collects baseline health surveys at 102 enrollment and uses several means to collect longitudinal health data, including continuous 103 abstraction of EHR data in the form of billing codes, laboratory and medication data, radiology reports, 104 and linkage with other data sources, such as national death indexes, pharmacy data, health care 105 claims data, and geospatially linked environmental data. The All of Us data used for this analysis were 106 collected between May 2018 and July 2023. Data from All of Us (https://www.researchallofus.org) is 107 available to researchers by application. The All of Us institutional review board approved the study 108 protocol for this study. All participants or their legally designated surrogates provided written informed 109 consent. In the present nested study, we included participants with both whole genome sequencing 110 (WGS) data and EHR data.

111

## 112 Genomic data

113 DNA was isolated from blood and saliva samples obtained at dedicated research centers across the

114 US, and WGS data were generated as described previously<sup>9</sup>. WGS data were quality controlled

115 centrally using standardized pipelines that follow the most up-to-date standards in the field.

116

## 117 Genetic ancestry ascertainment

118 Ancestry was ascertained centrally by the All of Us team using principal components analysis on

119 WGS data by comparing participants with reference datasets from diverse populations. Each

120 participant was assigned to: African, East Asian, South Asian, West Asian, European, L/A or Other.

- 121 For the rest of the analysis, we only included participants belonging to the three largest ancestry
- 122 groups: European, African, and L/A.

## 123

## 124 Exposure ascertainment

- 125 Our exposure of interest was polygenic susceptibility to MS modeled through a PRS, a well-
- 126 established tool in statistical genetics that estimates an individual's genetic burden across numerous
- 127 genetic risk variants.<sup>10</sup> For a given study participant, the polygenic risk score is the sum of the product
- 128 of the risk allele counts for each variant multiplied by the allele's reported effect on MS. The score
- 129 used genetic information on 282 independent genetic risk variants known to be associated with higher
- 130 risk of MS. These genetic risk variants are single nucleotide polymorphisms with a minor allele
- 131 frequency >1%, independent (r2, a measure of the correlation between variants, <0.1), biallelic
- 132 (involve two alleles only) and associated with the risk of MS at genome-wide levels (P<5x10-8),
- 133 following best practices for PRS generation.<sup>3</sup>
- 134

# 135 Outcome assessment

- 136 Corresponding ICD-10, and Systemized Nomenclature of Medicine (SNOMED) codes were used to
- 137 ascertain MS. Relative to baseline assessment, both prevalent and incident MS events were counted.
- 138

# 139 Statistical analysis

140 We present discrete variables as counts (percentage [%]) and continuous variables as mean 141 (standard deviation [SD]) or median (interquartile range [IQR]), as appropriate. Unadjusted 142 comparisons were made using chi-square tests for discrete variables and t or ANOVA tests, as 143 appropriate, for continuous variables. The three genetic ancestries considered (European, African, 144 L/A) were randomly sampled to obtain three populations of equivalent sizes. In each population, we 145 normalized the PRS (by subtracting the mean and dividing by the standard deviation) and divided it 146 into guintiles to establish five risk categories (very low, low, intermediate, high and very high polygenic 147 risk). To assess the relationship between the PRS and the risk of MS in each population, we used 148 multivariable logistic regression models adjusting for age, sex, and the first four genetic principal 149 components.

150

151

#### Results

## 152 Cohort characteristics

153 Of 413,457 participants included in the All of Us Research Program, 103,125 did not have EHR data,

154 137,179 did not have WGS data, and 173,153 were included in our analysis (mean age: 51.6 (SD:

155 17), 60% female). The distribution of genetic ancestry was as follows: 95,971 (55.4%) participants of

156 European, 37,674 (21.8%) of African, 32,428 (18.7%) of L/A, 4,040 (2.3%) of East Asian, 2,365

157 (1.4%) of South Asian, and 675 (0.4%) of Middle Eastern genetic ancestry (Table 1). To obtain three

158 populations of equal sizes, we randomly sampled 32,428 participants from the African and European

- 159 populations to match the number of L/A participants.
- 160

## 161 Unadjusted analysis

162 In each sample of 32,428 participants, there were 327 (1.0%) MS cases in the European group, 183

163 (0.56%) in the African group, and 150 (0.46%) in the L/A group. In the European population, the

164 proportion of MS cases ranged from 0.66% in the lowest PRS quintile to 1.59% in the highest PRS

165 quintile (p-value < 0.001 - Figure 1). In the African population, the proportion of MS cases did not

166 increase consistently across PRS categories with the same strength. The smallest proportion (0.45%)

167 occurred in the intermediate (3rd) PRS quintile, while the highest (0.82%) was in the highest PRS

168 quintile (p-value: 0.06). In the L/A population, the proportion of MS cases increased by PRS quintile,

ranging from 0.23% in the lowest quintile to 0.63% in the highest (p-value < 0.001).

170

## 171 Adjusted analysis

172 In multivariable logistic regression adjusting for age, sex, and genetic principal components, we found

173 that the PRS provided effective risk stratification in the European population. The odds of MS

174 increased by 51% (Odds Ratio: 1.51, 95% CI: [1.03-2.25]) in the intermediate PRS quintile and by

175 141% (OR: 2.41 [1.69-3.50]) in the highest PRS quintile compared to the lowest (test for trend p-

value: <0.0001 - Figure 2). In the African population, the PRS did not significantly stratify participants

177 into different MS risk categories (test-for-trend p-value: 0.10). Conversely, in the L/A population, the

178 PRS effectively stratified risk across several categories. The odds of MS increased by 85% (Odds

179 Ratio: 1.85, 95% CI: [1.00-3.56]) in the intermediate PRS quintile and by 156% (OR: 2.56 [1.45-4.78])

180 in the highest quintile compared to the lowest (test-for-trend p-value: 0.0004).

181

182

## Discussion

183 In this study, we evaluated the effectiveness of a PRS for MS across different genetic ancestries using 184 data from the All of Us Research Program. Our findings reveal significant disparities in the utility of the 185 PRS among European, African, and L/A populations, highlighting the necessity for tailored genetic risk 186 prediction tools in diverse populations.

187

The PRS effectively stratified MS risk in European and L/A individuals, with higher PRS quintiles corresponding to significantly increased odds of MS. This confirms the robustness of PRS derived from predominantly European GWAS data for these groups. Specifically, individuals in the highest PRS quintile had significantly elevated odds of developing MS compared to those in the lowest quintile, consistent with previous studies demonstrating the potential of PRS in risk stratification and early disease identification<sup>2,11</sup>.

194

195 Conversely, the PRS did not significantly stratify MS risk among individuals of African ancestry. This 196 discrepancy may stem from several factors. Primarily, the limited representation of African populations 197 in existing GWAS likely results in PRS that are less applicable to this group<sup>12</sup>. The genetic variants 198 contributing to MS risk in Europeans may not have the same effect in African populations, indicating 199 differences in the genetic architecture of MS across ancestries<sup>13</sup>. Additionally, gene-environment 200 interactions could play a role; genetic variants might interact with environmental factors differently 201 across populations, affecting disease risk in ways that a PRS developed in one population cannot 202 capture<sup>14</sup>. For instance, lifestyle, diet, and exposure to certain environmental factors can vary widely 203 between populations, influencing how genetic predispositions manifest as disease. Moreover, African populations possess greater genetic diversity compared to European populations<sup>15,16</sup>. This diversity 204 205 means the distribution of genetic variants is broader, including many that may be rare or absent in 206 European populations. As a result, a PRS developed using European data may not account for the full 207 range of genetic factors influencing MS risk in African populations. This genetic diversity complicates 208 the direct application of PRS across different ancestries, necessitating the development of population-209 specific PRS to ensure accurate and equitable risk prediction.

210

Our study also highlights the importance of utilizing large, diverse datasets like the All of Us Research
 Program to evaluate genetic tools' performance across populations. Such datasets are invaluable for

understanding complex diseases' genetic basis in diverse groups and developing inclusive geneticrisk prediction models.

215

216	This study has several limitations that warrant consideration. Firstly, the absolute risk of MS in the
217	population is low, which may limit the practical utility of the PRS as a stand-alone screening tool.
218	Given the multifactorial nature of MS, a comprehensive screening approach that incorporates genetic,
219	environmental, and lifestyle factors may be necessary to more accurately identify individuals at risk.
220	Additionally, the performance of the PRS in the All of Us dataset was lower compared to its
221	performance in other large datasets, such as the UK Biobank, even when considering individuals of
222	European ancestry only <sup>2</sup> . This discrepancy suggests that specific factors or characteristics unique to
223	the All of Us dataset, beyond genetic ancestry, may influence PRS performance. Factors such as
224	differences in data collection methods, population heterogeneity, or unmeasured environmental
225	influences could contribute to this variation.
226	
227	In conclusion, while the PRS for MS is effective in European and L/A populations, it is less effective
228	for African ancestry individuals. This emphasizes the urgent need for inclusive genetic research and
229	the development of ancestry-specific PRS to ensure equitable benefits from genetic risk prediction
230	and personalized healthcare. Future studies should focus on expanding genetic diversity in research
231	cohorts, improving underrepresented populations' representation in GWAS, and refining PRS
232	methodologies to enhance their applicability across all populations, ultimately advancing the goal of
233	personalized medicine for all.
234	
235	Data availability statement

This study used data from the All of Us Research Program's Controlled Tier Dataset C2022Q4R9 and Registered Tier Dataset R2022Q4R9, available to authorized users on the Researcher Workbench via <u>www.allofus.nih.gov</u>. All data access and analyses were conducted within a secure informatic workspace provided by the National Institutes of Health.

240


### References

- 1. Dobson R, Giovannoni G. Multiple sclerosis a review. *Eur J Neurol.* 2019;26(1):27-40. doi:10.1111/ene.13819
- Shams H, Shao X, Santaniello A, et al. Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans. *Brain.* 2023;146(2):645-656. doi:10.1093/brain/awac092
- INTERNATIONAL MULTIPLE SCLEROSIS GENETICS CONSORTIUM. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. *Science*. 2019;365(6460):eaav7188. doi:10.1126/science.aav7188
- Loginovic P, Wang F, Li J, et al. Applying a genetic risk score model to enhance prediction of future multiple sclerosis diagnosis at first presentation with optic neuritis. *Nat Commun.* 2024;15(1):1415. doi:10.1038/s41467-024-44917-9
- 5. Choi SW, Mak TSH, O'Reilly PF. A guide to performing Polygenic Risk Score analyses. *Nat Protoc.* 2020;15(9):2759-2772. doi:10.1038/s41596-020-0353-1
- Natarajan P, Young R, Stitziel NO, et al. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. *Circulation*. 2017;135(22):2091-2101. doi:10.1161/CIRCULATIONAHA.116.024436
- Peterson RE, Kuchenbaecker K, Walters RK, et al. Genome-wide association studies in ancestrally diverse populations: opportunities, methods, pitfalls, and recommendations. *Cell*. 2019;179(3):589-603. doi:10.1016/j.cell.2019.08.051
- 8. All of Us Research Program Investigators, Denny JC, Rutter JL, et al. The "All of Us" Research Program. *N Engl J Med*. 2019;381(7):668-676. doi:10.1056/NEJMsr1809937
- 9. Devaney S. All of Us. Nature. 2019;576(7785):S14-S17. doi:10.1038/d41586-019-03717-8
- Vaura F, Kauko A, Suvila K. Polygenic Risk Scores Predict Hypertension Onset and Cardiovascular Risk. *Hypertens Dallas Tex.* 1979;2021;77(4):1119-1127. doi:10.1161/HYPERTENSIONAHA.120.16471
- 11. Klarin D, Natarajan P. Clinical utility of polygenic risk scores for coronary artery disease. *Nat Rev Cardiol.* Published online November 22, 2021:1-11. doi:10.1038/s41569-021-00638-w
- Ruan Y, Lin YF, Feng YCA, et al. Improving polygenic prediction in ancestrally diverse populations. *Nat Genet*. 2022;54(5):573-580. doi:10.1038/s41588-022-01054-7
- Beecham AH, Amezcua L, Chinea A, et al. The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States. *Mult Scler*. 2020;26(11):1329-1339. doi:10.1177/1352458519863764
- Virolainen SJ, VonHandorf A, Viel KCMF, Weirauch MT, Kottyan LC. Gene-environment interactions and their impact on human health. *Genes Immun.* 2023;24(1):1-11. doi:10.1038/s41435-022-00192-6
- Pereira L, Mutesa L, Tindana P, Ramsay M. African genetic diversity and adaptation inform a precision medicine agenda. *Nat Rev Genet*. 2021;22(5):284-306. doi:10.1038/s41576-020-00306-8
- 16. Yu N, Chen FC, Ota S, et al. Larger genetic differences within africans than between Africans and Eurasians. *Genetics*. 2002;161(1):269-274.

# Tables and figures (3 max)

# Table 1. Cohort characteristics

	MS (N = 1,364)	No MS (N= 171,789)	P value
Age at enrollment, mean (SD)	52.27 (13.7)	51.58 (17.0)	0.138
Female	1,055 (77.3)	103,141 (60.0)	<0.001
Genetic ancestry EUR AFR AMR EAS SAS MID	971 (71.2) 214 (15.7) 150 (11.0) <20 <20 <20	37,460 (21.8)	<0.001
Smoking Current Previous	176 (13.2) 403 (30.3)	27,640 (16.6) 38,903 (23.3)	<0.001
Body Mass Index <25 25-30 >=30	403 (31.0) 397 (30.5) 501 (38.5)		0.047



# Figure 1. Proportions of MS cases by PRS quintile in European, African, and L/A ancestry populations

Figure 2. Adjusted odds ratios of MS diagnosis by PRS quintile in European, African, and L/A ancestry populations

